We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 07, 2020

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft-Tissue Sarcomas Who Are Not Candidates for Chemotherapy

European Journal of Cancer

 

Additional Info

European Journal of Cancer
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft-Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Eur. J. Cancer 2020 Oct 01;137(xx)1-9, AC Hirbe, V Eulo, CI Moon, J Luo, S Myles, M Seetharam, J Toeniskoetter, T Kershner, S Haarberg, M Agulnik, V Monga, M Milhem, A Parkes, S Robinson, S Okuno, S Attia, BA Van Tine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading